Home›Toremifene Citrate

Toremifene Citrate

Also known as: Toremifene Citrate

Route: Oral

38 interactions on record⛔ Black Box Warning

Toremifene Citrate has 38 known drug interactions based on U.S. FDA drug labeling data. 34 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Amiodarone, Amitriptyline, Atazanavir. Patients taking Toremifene Citrate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 38
Major: 34
Moderate: 2

Major (34)

Toremifene Citrate + Amiodarone— Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitori…
Toremifene Citrate + Amitriptyline— Antidepressant that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Atazanavir— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Carbamazepine— Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Clarithromycin— Antibiotic and strong CYP3A4 inhibitor that prolongs QT interval; increases toremifene exposure and should be avoided.
Toremifene Citrate + Dexamethasone— Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Disopyramide— Class IA antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitorin…
Toremifene Citrate + Dofetilide— Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitori…
Toremifene Citrate + Erythromycin— Antibiotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Granisetron— Anti-emetic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Haloperidol— Antipsychotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Ibutilide— Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitori…
Toremifene Citrate + Indinavir— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Itraconazole— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Ketoconazole— Strong CYP3A4 inhibitor that increases toremifene Cmax 1.4-fold and AUC 2.9-fold; should be avoided.
Toremifene Citrate + Levofloxacin— Antibiotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Nefazodone— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Nelfinavir— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Ofloxacin— Antibiotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Ondansetron— Anti-emetic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Phenobarbital— Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Phenytoin— Strong CYP3A4 inducer that decreases toremifene exposure; also a CYP2C9 substrate requiring careful monitoring.
Toremifene Citrate + Procainamide— Class IA antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitorin…
Toremifene Citrate + Quinidine— Class IA antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitorin…
Toremifene Citrate + Rifabutin— Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Rifampin— Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Ritonavir— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Saquinavir— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Sotalol— Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitori…
Toremifene Citrate + St. John'S Wort— Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Telithromycin— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.
Toremifene Citrate + Thioridazine— Antipsychotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Venlafaxine— Antidepressant that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Toremifene Citrate + Voriconazole— Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Moderate (2)

Toremifene Citrate + Andthiazide— Thiazide diuretics decrease renal calcium excretion and may increase the risk of hypercalcemia in patients receiving tor…
Toremifene Citrate + Warfarin— CYP2C9 substrate with narrow therapeutic index; use with caution and require careful monitoring.

Toremifene Citrate + Amiodarone⚠️Major

Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Amitriptyline⚠️Major

Antidepressant that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Atazanavir⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Carbamazepine⚠️Major

Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Clarithromycin⚠️Major

Antibiotic and strong CYP3A4 inhibitor that prolongs QT interval; increases toremifene exposure and should be avoided.

Toremifene Citrate + Dexamethasone⚠️Major

Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Disopyramide⚠️Major

Class IA antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Dofetilide⚠️Major

Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Erythromycin⚠️Major

Antibiotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Granisetron⚠️Major

Anti-emetic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Haloperidol⚠️Major

Antipsychotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Ibutilide⚠️Major

Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Indinavir⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Itraconazole⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Ketoconazole⚠️Major

Strong CYP3A4 inhibitor that increases toremifene Cmax 1.4-fold and AUC 2.9-fold; should be avoided.

Toremifene Citrate + Levofloxacin⚠️Major

Antibiotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Nefazodone⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Nelfinavir⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Ofloxacin⚠️Major

Antibiotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Ondansetron⚠️Major

Anti-emetic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Phenobarbital⚠️Major

Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Phenytoin⚠️Major

Strong CYP3A4 inducer that decreases toremifene exposure; also a CYP2C9 substrate requiring careful monitoring.

Toremifene Citrate + Procainamide⚠️Major

Class IA antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Quinidine⚠️Major

Class IA antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Rifabutin⚠️Major

Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Rifampin⚠️Major

Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Ritonavir⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Saquinavir⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Sotalol⚠️Major

Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + St. John'S Wort⚠️Major

Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Telithromycin⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Thioridazine⚠️Major

Antipsychotic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Venlafaxine⚠️Major

Antidepressant that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

Toremifene Citrate + Voriconazole⚠️Major

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Toremifene Citrate + Andthiazide🟡Moderate

Thiazide diuretics decrease renal calcium excretion and may increase the risk of hypercalcemia in patients receiving toremifene citrate.

Toremifene Citrate + Warfarin🟡Moderate

CYP2C9 substrate with narrow therapeutic index; use with caution and require careful monitoring.

Toremifene Citrate + Midazolamℹ️Unknown

7.5 Effect of Toremifene on CYP3A4 Substrates In a study of 20 healthy subjects, 2 mg midazolam once daily (days 6 and 18) coadministered with toremifene as a 480 mg loading dose followed by 80 mg once daily for 16 days. Following coadministration on days 6 and 18 relevant increases in midazolam and α-hydroxymidazolam Cmax and AUC were not observed. Following coadministration on day 18 midazolam and α-hydroxymidazolam Cmax and AUC were reduced by less than 20%.

Toremifene Citrate + Tolbutamideℹ️Unknown

7.6 Effect of Toremifene on CYP2C9 Substrates In a study of 20 healthy subjects, 500 mg tolbutamide once daily (days 7 and 19) coadministered with toremifene as a 480 mg loading dose followed by 80 mg once daily for 16 days. Following coadministration on days 7 and 19 plasma tolbutamide Cmax and AUC were increased by less than 30%. A reduction of similar magnitude was observed for hydroxytolbutamide and carboxytolbutamide Cmax and AUC.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.